- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06564844
En randomiserad fas III-studie av adjuvant Dato-DXd i kombination med Rilvegostomig eller Rilvegostomig monoterapi kontra standardvård, efter fullständig tumörresektion, hos deltagare med stadium I Adenocarcinom NSCLC som är ctDNA-positiva eller har högriskpatologiska egenskaper (TROPION-Lung12)
En fas III, randomiserad, öppen, global studie av adjuvans datopotamab deruxtecan (Dato-DXd) i kombination med rilvegostomig eller rilvegostomig monoterapi kontra standardvård, efter fullständig tumörresektion, hos deltagare med stadium I adenocarcinom lungcancer Vilka är ctDNA-positiva eller har högriskpatologiska egenskaper (TROPION-Lung12)
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Barretos, Brasilien, 14784-057
- Research Site
-
Brasília, Brasilien, 70200-730
- Research Site
-
Florianópolis, Brasilien, 88034-000
- Research Site
-
São Paulo, Brasilien, 01323-903
- Research Site
-
Teresina, Brasilien, 64049-200
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, Förenta staterna, 85724
- Research Site
-
-
California
-
Duarte, California, Förenta staterna, 91010
- Research Site
-
Glendale, California, Förenta staterna, 91204
- Research Site
-
Los Angeles, California, Förenta staterna, 90089
- Research Site
-
-
Colorado
-
Lone Tree, Colorado, Förenta staterna, 80124
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20007
- Research Site
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32224
- Research Site
-
St. Petersburg, Florida, Förenta staterna, 33709
- Research Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- Research Site
-
Evanston, Illinois, Förenta staterna, 60201
- Research Site
-
Zion, Illinois, Förenta staterna, 60099
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21237
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Research Site
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55407
- Research Site
-
-
Montana
-
Billings, Montana, Förenta staterna, 59102
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68130
- Research Site
-
-
New York
-
East Syracuse, New York, Förenta staterna, 13057
- Research Site
-
Mineola, New York, Förenta staterna, 11501
- Research Site
-
New York, New York, Förenta staterna, 10016
- Research Site
-
New York, New York, Förenta staterna, 10065
- Research Site
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Förenta staterna, 18015
- Research Site
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Research Site
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37920
- Research Site
-
Memphis, Tennessee, Förenta staterna, 38120
- Research Site
-
Nashville, Tennessee, Förenta staterna, 37203
- Research Site
-
-
Texas
-
Austin, Texas, Förenta staterna, 78745
- Research Site
-
Dallas, Texas, Förenta staterna, 75231
- Research Site
-
Houston, Texas, Förenta staterna, 77030
- Research Site
-
San Antonio, Texas, Förenta staterna, 78217
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Research Site
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98104
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Research Site
-
-
-
-
-
Bunkyō City, Japan, 113-8603
- Research Site
-
Chiba, Japan, 260-0877
- Research Site
-
Chūōku, Japan, 104-0045
- Research Site
-
Fukuoka, Japan, 812-8582
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Research Site
-
Hiroshima, Japan, 734-8551
- Research Site
-
Hiroshima, Japan, 730-8518
- Research Site
-
Iwakuni-shi, Japan, 740-8510
- Research Site
-
Kashiwa, Japan, 277-8577
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Research Site
-
Kobe, Japan, 650-0017
- Research Site
-
Kumamoto, Japan, 860-8556
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Nagoya, Japan, 464-8681
- Research Site
-
Niigata, Japan, 951-8566
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Research Site
-
Sapporo, Japan, 003-0804
- Research Site
-
Sendai, Japan, 980-8574
- Research Site
-
Sendai, Japan, 980-0873
- Research Site
-
Wakayama, Japan, 641-8510
- Research Site
-
Yokohama, Japan, 241-8515
- Research Site
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 2Y9
- Research Site
-
-
Ontario
-
Oshawa, Ontario, Kanada, L1G 2B9
- Research Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 3J4
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Kuala Lumpur, Malaysia, 50586
- Research Site
-
Kuching, Malaysia, 93586
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 112
- Research Site
-
Taipei, Taiwan, 114
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Research Site
-
Bangkoknoi, Thailand, 10700
- Research Site
-
Banphaeo, Thailand, 74120
- Research Site
-
Dusit, Thailand, 10300
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Muang, Thailand, 50200
- Research Site
-
Muang, Thailand, 40002
- Research Site
-
Ratchathewi, Thailand, 10400
- Research Site
-
-
-
-
-
Ankara, Turkiet (Türkiye), 06280
- Research Site
-
Ankara, Turkiet (Türkiye), 06010
- Research Site
-
Mersin, Turkiet (Türkiye), 33240
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Research Site
-
Hà Nội, Vietnam, 100000
- Research Site
-
Vinh, Vietnam, 460000
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
- Complete surgical resection (R0) of the primary NSCLC
- Unequivocal no evidence of disease at post-surgical
- Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
- ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Sensitizing EGFR mutation and/or ALK alteration
- History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Significant pulmonary function compromise
- History of another primary malignancy within 3 years (with exceptions)
- Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
- Clinically significant corneal disease
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Dato-DXd + rilvegostomig
Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Datopotamab Deruxtecan IV (intravenous)
Andra namn:
Rilvegostomig IV (intravenous)
Andra namn:
|
|
Experimentell: Rilvegostomig
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Rilvegostomig IV (intravenous)
Andra namn:
|
|
Aktiv komparator: Standard of Care (SoC)
Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC). |
Carboplatin IV (intravenous), Active Comparator Cisplatin IV (intravenous), Active Comparator Etoposide IV (intravenous), Active Comparator Pemetrexed IV (intravenous), Active Comparator Vinorelbine IV (intravenous), Active Comparator UFT Oral route of administration, Active Comparator |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsram: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsram: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
|
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsram: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsram: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Pharmacokinetics (PK)
Tidsram: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Tidsram: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of rilvegostomig in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Tidsram: Up to 30 or 90 days post-last dose of study intervention.
|
PK parameters (peak and through concentrations). |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Immunogenicity
Tidsram: Up to 30 or 90 days post-last dose of study intervention.
|
Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples). |
Up to 30 or 90 days post-last dose of study intervention.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: David Jones, MD, Memorial Sloan Kettering Cancer Center, New York, United States of America
- Huvudutredare: Enriqueta Felip, MD, Vall d'Hebron Hospital, Barcelona, Spain
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Lungsjukdomar
- Neoplasmer, körtel och epitel
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Carcinom
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Karcinom, icke-småcellig lunga
- Adenocarcinom
- Aminosyror, peptider och proteiner
- Organiska kemikalier
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Kolväten
- Kolväten, cykliska
- Kolhydrater
- Alkaloider
- Podofyllotoxin
- Tetrahydronaftaler
- Naftalar
- Polycykliska aromatiska kolväten
- Kolväten, aromatisk
- Polycykliska föreningar
- Glukosider
- Glykosider
- Förenad
- Oorganiska kemikalier
- Klorföreningar
- Kväveföreningar
- Koordinationskomplex
- Guanin
- Hypoxantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyror, sur
- Aminosyror
- Aminosyror, dikarboxyl
- Vinca alkaloider
- Secologanin tryptaminalkaloider
- Indolalkaloider
- Indolizidiner
- Indoliziner
- Platinaföreningar
- Vinorelbin
- Pemetrexed
- Etoposid
- Karboplatin
- Cisplatin
Andra studie-ID-nummer
- D926TC00001
- 2024-512195-35-00 (Registeridentifierare: CTIS)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tidsram för IPD-delning
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kriterier för IPD Sharing Access
When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .